Cover Image
市場調查報告書

Sodium Ibandronate的中國市場分析

Investigation Report on China Sodium Ibandronate Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 333635
出版日期 內容資訊 英文 30 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
Sodium Ibandronate的中國市場分析 Investigation Report on China Sodium Ibandronate Market, 2010-2019
出版日期: 2015年06月25日 內容資訊: 英文 30 Pages
簡介

中國國內每年產生300萬人以上的新癌症患者,其中約50%為骨轉移性癌症的患者。Sodium Ibandronate是1996年在德國和奧地利認證的抗骨轉移性癌症藥物,經過更方便的投藥法的開發,2005年也受美國認證。Sodium Ibandronate到近幾年,在中國國內急速擴大其年度銷售額,2010年達5038萬人民幣,2014年達8723萬人民幣,以年複合成長率(CAGR) 14.71%的速度成長。

本報告提供中國的Sodium Ibandronate的市場相關分析、整體市場規模趨勢(過去5年份)和國內價格趨勢、各企業、各投藥形態的市場佔有率、主要製造商簡介、未來性的市場趨勢預測(今後5年份)等調查評估。

第1章 Sodium Ibandronate的相關概念

  • 適應症
  • 全球市場的銷售情形

第2章 中國的Sodium Ibandronate的市場簡介

  • 中國的Sodium Ibandronate的專利、核准狀況
  • 主要製造商
  • 市場規模

第3章 中國的Sodium Ibandronate銷售情形的相關調查 (過去5年份)

  • 銷售額
    • 整體銷售額
    • 各地區的銷售額
  • 銷售量
    • 整體銷售量
    • 各地區的銷售量

第4章 中國的Sodium Ibandronate的龍頭製造商的市場佔有率的相關調查 (過去5年份)

  • 出售價值的市場佔有率
  • 銷售數量的市場佔有率

第5章 中國的Sodium Ibandronate的劑型相關調查 (過去5年份)

  • 各劑型的市場佔有率 (銷售額為基礎)
  • 各劑型的市場佔有率 (銷售量為基礎)

第6章 中國國內的Sodium Ibandronate的醫院用標準價格

  • Roche Diagnostics GmbH GE (商標名:BONVIVA)
  • Hencer Pharmacy (商標名:Jia Nuo Shun)
  • Easton Pharmaceutical Co., Ltd
  • Science & Technology General Company Hebei Medical University (商標名:Aiben)

第7章 在中國市場的Sodium Ibandronate的龍頭製造商 (過去5年份)

  • Hencer Pharmacy
  • Science & Technology General Company Hebei Medical University
  • Roche Diagnostics GmbH
  • Easton Pharmaceutical Co., Ltd

第8章 中國的Sodium Ibandronate的市場未來展望 (今後5年份)

  • 市場規模的預測
  • 競爭環境的預測

圖表一覽

目錄
Product Code: 1506240

Bone metastasis is common in patients with advanced malignant tumor. According to the statistics, each year millions of tumor patients especially patients with breast cancer, prostate cancer and lung cancer suffer from bone metastasis around the world. Bone metastasis of malignant tumor often result in severe lesions in bone including such skeletal-related events as bone pain, pathological fracture, spinal cord compression and hypercalcemia. Once Bone metastasis occurs, most patients will suffer from different degrees of pain even pathological fracture, which will obviously influence their life quality.

The most common drug for bone metastasis is diphosphonate. Three generations of diphosphonate, respectively, etidronate and clodronate representated by Bonefos, pamidronate and alendronate sodium represented by Bonin as well as sodium ibandronate and zoledronic acid are now used in the clinic.

First registered and used in the clinic under the trade name of Bondronat in Germany and Austria in 1996, sodium ibandronate was approved by FDA to come into the market as a daily treatment of osteoporosis under the trade name of Boniva. However, since drug makers later developed more convenient dose, Boniva has not appeared in the American market until FDA approved its monthly use in 2005.

The number of new cases of cancer is over 3 million each year in China, among which about 50% suffer from bone metastasis. In 2001, some local enterprises began to apply for relevant products of sodium ibandronate and succeeded in 2002. In Jul. 2006, sodium ibandronate produced by Roche entered China under the trade name of Bondronat. Since then, sodium ibandronate has developed fast, annual sales value rising from CNY 50.38 million in 2010 to CNY 87.23 million in 2014 and CAGR during this period reaching up to 14.71%. Sodium ibandronate enjoys a vast demand in China. Currently, sodium ibandronate market in China is mainly occupied by the following companies: Science & Technology General Company Hebei Medical University, Roche Diagnostics GmbH GE), Hencer Pharmacy and Easton Pharmaceutical Co., Ltd, among which Science & Technology General Company Hebei Medical University has the largest market share of about 58% for sales value in 2014.

With the degradation of environmental pollution and the ageing population, the number of new cases of cancer each year is expected to keep increasing, which shall boost the growth of sodium ibandronate market in China.

Readers can get at least the following information from this report:

  • market size of sodium ibandronate in China
  • competitive landscape of sodium ibandronate in Chinese market
  • price of sodium ibandronate made by different enterprises in China
  • market outlook of sodium ibandronate in China

The author suggests the following groups of people purchase this report:

  • manufacturers of anti-tumor drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Sodium Ibandronate

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Sodium Ibandronate in China

  • 2.1. Patent and Approval Status of Sodium Ibandronate in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Sodium Ibandronate in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Sodium Ibandronate in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Sodium Ibandronate in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Sodium Ibandronate in Chinese Hospitals in 2014

  • 6.1. Roche Diagnostics GmbH GE (Trade Name: BONVIVA)
  • 6.2. Hencer Pharmacy (Trade Name: Jia Nuo Shun)
  • 6.3. Easton Pharmaceutical Co., Ltd
  • 6.4. Science & Technology General Company Hebei Medical University (Trade Name: Aiben)

7. Major Manufacturers of Sodium Ibandronate in Chinese Market, 2010-2014

  • 7.1. Hencer Pharmacy
  • 7.2. Science & Technology General Company Hebei Medical University
  • 7.3. Roche Diagnostics GmbH
  • 7.4. Easton Pharmaceutical Co., Ltd

8. Market Outlook of Sodium Ibandronate in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Table of Selected Charts

  • Chart Approval Information of Sodium Ibandronate in China
  • Chart Sales Status of Sodium Ibandronate in China
  • Chart Sales Value of Sodium Ibandronate in China, 2010-2014
  • Chart Sales Value of Sodium Ibandronate in Some Regions in China, 2010-2014
  • Chart Sales Volume of Sodium Ibandronate in China, 2010-2014
  • Chart Market Share of TOP4 Manufacturers of Sodium Ibandronate for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Sodium Ibandronate Made by Science & Technology General Company Hebei Medical University in China, 2010-2014
  • Chart Sales Value and Market Share of Sodium Ibandronate Made by Hencer Pharmacy in China, 2010-2014
  • Chart Sales Value and Market Share of Sodium Ibandronate Made by Roche Diagnostics(GE) in China, 2010-2014
  • Chart Sales Value and Market Share of Sodium Ibandronate Made by Easton in China, 2010-2014
  • Chart Price of Sodium Ibandronate Made by Roche Diagnostics GmbH GE in Some Chinese Cities in 2014
  • Chart Price of Sodium Ibandronate Made by Hencer Pharmacy in Some Chinese Cities in 2014
  • Chart Price of Sodium Ibandronate Made by Easton Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Sodium Ibandronate Made by Science & Technology General Company Hebei Medical University in Some Chinese Cities in 2014
Back to Top